iTeos Therapeutics, Inc. (NASDAQ:ITOS) Receives $15.50 Consensus PT from Analysts

Key Points

• iTeos Therapeutics, Inc. has received a consensus rating of "Hold" from seven brokerage firms, with an average target price of $15.50.
• The company reported a quarterly earnings per share (EPS) of ($1.51), missing the consensus estimate by ($0.39).
• Recent insider selling included Director David Hallal offloading 38,228 shares and CEO Michel Detheux selling 43,883 shares, indicating a significant decrease in insider ownership.

Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS - Get Free Report) have received an average rating of "Hold" from the seven research firms that are presently covering the company, Marketbeat reports. Six investment analysts have rated the stock with a hold recommendation and one has assigned a buy recommendation to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $15.50.

A number of analysts have recently commented on the company. Leerink Partnrs cut iTeos Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, May 14th. Piper Sandler cut iTeos Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Monday, July 21st. Wells Fargo & Company decreased their target price on iTeos Therapeutics from $12.00 to $11.00 and set an "equal weight" rating for the company in a research report on Thursday, August 7th. HC Wainwright cut iTeos Therapeutics from a "buy" rating to a "neutral" rating in a research report on Wednesday, May 14th. Finally, JPMorgan Chase & Co. cut iTeos Therapeutics from an "overweight" rating to a "neutral" rating and decreased their target price for the company from $15.00 to $8.00 in a research report on Tuesday, May 13th.

Insider Transactions at iTeos Therapeutics

In related news, CEO Michel Detheux sold 43,883 shares of the business's stock in a transaction dated Tuesday, June 10th. The stock was sold at an average price of $10.02, for a total value of $439,707.66. Following the transaction, the chief executive officer owned 153,903 shares in the company, valued at $1,542,108.06. The trade was a 22.19% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director David Hallal sold 38,228 shares of the business's stock in a transaction dated Friday, June 6th. The shares were sold at an average price of $10.24, for a total value of $391,454.72. The disclosure for this sale can be found here. Over the last three months, insiders sold 277,185 shares of company stock valued at $2,805,412. Insiders own 14.20% of the company's stock.

Hedge Funds Weigh In On iTeos Therapeutics

Several institutional investors have recently added to or reduced their stakes in ITOS. Geode Capital Management LLC increased its position in iTeos Therapeutics by 0.7% in the 4th quarter. Geode Capital Management LLC now owns 644,901 shares of the company's stock valued at $4,954,000 after acquiring an additional 4,551 shares during the period. Wells Fargo & Company MN boosted its holdings in iTeos Therapeutics by 16.9% in the 4th quarter. Wells Fargo & Company MN now owns 16,644 shares of the company's stock valued at $128,000 after purchasing an additional 2,402 shares in the last quarter. Russell Investments Group Ltd. boosted its holdings in iTeos Therapeutics by 115.1% in the 4th quarter. Russell Investments Group Ltd. now owns 57,225 shares of the company's stock valued at $439,000 after purchasing an additional 30,619 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in iTeos Therapeutics in the 4th quarter valued at approximately $1,159,000. Finally, Barclays PLC boosted its holdings in iTeos Therapeutics by 17.4% in the 4th quarter. Barclays PLC now owns 132,894 shares of the company's stock valued at $1,022,000 after purchasing an additional 19,683 shares in the last quarter. Institutional investors and hedge funds own 97.16% of the company's stock.

iTeos Therapeutics Stock Performance

iTeos Therapeutics stock remained flat at $10.13 during midday trading on Friday. The company's stock had a trading volume of 2,592,183 shares, compared to its average volume of 1,050,773. iTeos Therapeutics has a one year low of $4.80 and a one year high of $17.63. The stock has a market cap of $447.85 million, a P/E ratio of -2.17 and a beta of 1.49. The stock's fifty day moving average is $10.13 and its 200-day moving average is $8.39.

iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The company reported ($1.51) earnings per share for the quarter, missing analysts' consensus estimates of ($1.12) by ($0.39). As a group, equities research analysts forecast that iTeos Therapeutics will post -3.49 earnings per share for the current year.

iTeos Therapeutics Company Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.